RA Medical Systems Inc (NYSEAMERICAN: RMED) Posts A Drop Of 21.4% YoY In Q1 2021 Revenues

RA Medical Systems Inc (NYSEAMERICAN: RMED) reported revenues of $1.1 million (down 21.4% YoY) in Q1 2021. The company holds a cash balance and cash equivalents of $16 million at the end of Q1 2021. 

The cost of revenues is declined by $0.2 million to $1.4 million in Q1 2021. Its G&A expenses are $4.1 million. 

RA Medical’s R&D spending is increased by $1.5 million to $2.8 million in Q1 2021. Its loss is declined by $0.5 million to $7.2 million. 

Enrolls 20 subjects

RA Medical enrolled 20 candidates in its atherectomy pivotal clinical trial since mid-March 2021. With the lifting of coronavirus restrictions, the company improved revenues from its dermatology segment. 

RA Medical’s CEO, Will McGuire, is pleased with its recent progress in enrolling subjects for its atherectomy study. Its total enrolled subjects are reached 50 with the recent enrollment of 20 candidates.

The company has reported six months aging data using the next-gen DABRA catheter. McGuire said he is confident with this important milestone. The company now has robust data to support the extended shelf life of catheter. 

RA Medical’s products

Its product – DABRA is a minimally invasive excimer laser. Physicians utilize this disposable catheter to cure vascular blockages in below and above the knee in patients. 

DABRA dissolves plaques and reduces them into lipids, proteins, other chemical compounds. 

RA Medical has developed DABRA, the full aperture ratio, and liquid-filled catheter, to provide endovascular treatment to remove vascular blockages. It is beneficial compared to other therapies and treatments available in the market.

DABRA demonstrated its efficacy in removing a wide variety of blockages without the need to use a guidewire.

It utilizes a photochemical ablation to eliminate all blockage types by breaking the obstructing plaque bonds. 

DABRA will damage the arterial walls during the treatment. Therefore, it is safe to use DABRA compared to other treatments available for PAD in the market. 

DABRA showed 94% efficacy in a non-randomized and multi-site prospective study, which involved 64 subjects in removing the blockages. 

RA Medical also offers Pharos, a safe, powerful, and painless 308 nm UVB excimer laser, to cure atopic dermatitis, vitiligo, and psoriasis. The product is optimized to offer quick treatment. 

Leave a Comment

Your email address will not be published.